We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Netrins Reverse Damage in Mouse Model of Diabetes

By Biotechdaily staff writers
Posted on 12 Jul 2006
Researchers have used a mouse model to demonstrate that netrins, proteins that help guide axon growth in the developing embryo, are capable of reversing damage caused to nervous and vascular tissues in animals with diabetes.

In the developing nervous system, axon guidance and the establishment of
appropriate neuronal connections involve a number of chemo-attractant and
chemo-repellent molecules. More...
Netrins are related to the extracellular matrix protein laminin and comprise a family of secreted molecules capable of guiding the axon growth cone.

Investigators at the University of Utah (Salt Lake City, USA) had previously shown that netrin-1 promoted blood vessel growth in cell cultures. In the current study they treated ischemic and diabetic mice with netrin-1 and compared results to those obtained with vascular endothelial growth factor (VEGF), a known stimulator of vascular growth.

Their findings, published in the June 29, 2006, online edition of Science Express, revealed that in the ischemic mice netrin-1 and VEGF promoted blood vessel growth equally well. However, in the diabetic mice, netrin-1 was a significantly more potent stimulator of blood vessel and nerve growth than VEGF.

"We now have a factor that attracts both blood vessels and nerves--that is why it is unique for diabetes,” explained senior author Dr. Dean Y. Li, assistant professor of medicine at the University of Utah. "This demonstrates that netrins are critical for development and may be important as a new therapy.”



Related Links:
University of Utah

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
All-in-One Molecular System
AIO M160
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.